The U.S. Food and Drug Administration approved a new combination therapy pairing Eli Lilly’s targeted oral cancer drug Inluriyo with Verzenio for adults with specific advanced or metastatic breast cancers. The regulatory decision, issued on February 18, targets patients with ER-positive, HER2-negative tumors harboring ESR1 gene mutations who have experienced disease progression after at least one prior endocrine therapy.
Targeting Hormone Pathways and Cell Division
Inluriyo, also known generically as imlunestrant, functions as an oral complete estrogen receptor antagonist that targets estrogen receptors for degradation, cutting off the hormone signaling pathways that drive cancer cell proliferation. Verzenio, or abemaciclib, inhibits cyclin-dependent kinases CDK4 and 6, arresting cell cycle progression and halting division in cancer cells.
The approved dosing regimen requires patients to take Inluriyo 200mg as two tablets once daily alongside Verzenio 150mg taken as one tablet twice daily. This dual approach aims to overcome resistance mechanisms that frequently develop during standard endocrine treatments, particularly when secondary mutations alter the ESR1 gene.
Clinical Trial Results from EMBER-3
According to the Phase 3 EMBER-3 clinical trial results cited by regulatory filings, the approval is backed by data from 874 participants whose disease progressed despite prior treatment with aromatase inhibitors or CDK4/6 inhibitors. Within this cohort, researchers isolated a subgroup of 159 patients carrying confirmed ESR1 mutations.
Among those 159 patients, 67 received the combination of Inluriyo and Verzenio, while 92 received Inluriyo monotherapy. Data compiled from the trial show that the median progression-free survival reached 11.1 months for patients in the combination group, compared to 5.5 months for those taking Inluriyo alone. This represented a 47% reduction in the risk of disease progression or death for the combination cohort. Furthermore, overall tumor response rates reached 35% in the combination arm, contrasted with 15% in the monotherapy arm.
Regulatory Context and Safety Considerations
According to historical regulatory records, the FDA previously granted approval to Inluriyo as a standalone monotherapy in September 2025 for eligible patients with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer. The new February decision expands that label to include the Verzenio combination.
South Korea’s Ministry of Food and Safety approved Inluriyo 200mg as a standalone monotherapy on February 13 for adults with matching biomarkers following prior endocrine treatment, though the Verzenio combination therapy remains unapproved in that jurisdiction.
Prescribing information for Verzenio includes strict boxed warnings regarding severe adverse events, including diarrhea, neutropenia, hepatotoxicity, interstitial lung disease, pneumonitis, and venous thromboembolism. Because data collection regarding overall survival was immature at the time of the FDA’s review, researchers note that final impacts on overall survival remain to be established.
Related reading
- Why Project Hail Mary’s Optimism Resonates With Audiences
- Earl Spencer Accuses King Charles of Gaslighting in New Book
- Understanding Infusion Reactions in Cancer Treatment: Common Symptoms, Causes, and Essential Information for Patients – Cancer Treatment Side Effects and Complications (archyworldys.com)